Last reviewed · How we verify
ZOL
ZOL (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
ZOL (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Multiple myeloma with bone lesions, Metastatic bone disease from solid tumors, Osteoporosis.
At a glance
| Generic name | ZOL |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology, Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
Zoledronic acid binds to hydroxyapatite in bone and is taken up by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases essential for osteoclast function. This leads to osteoclast apoptosis and reduced bone resorption, making it effective for conditions characterized by excessive bone loss or osteolytic lesions.
Approved indications
- Multiple myeloma with bone lesions
- Metastatic bone disease from solid tumors
- Osteoporosis
- Paget's disease of bone
- Hypercalcemia of malignancy
Common side effects
- Osteonecrosis of the jaw
- Renal impairment
- Hypocalcemia
- Fever
- Myalgia/arthralgia
- Nausea
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (PHASE1, PHASE2)
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (PHASE1, PHASE2)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Zoledronate In the Prevention of Paget's Disease: Long Term Extension
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Contribution of Bone to Urine Citrate
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZOL CI brief — competitive landscape report
- ZOL updates RSS · CI watch RSS
- Eisai Inc. portfolio CI